
GLP-1 medicines and bariatric surgery: compare treatment pathways
Other prescription options, intensive behavioral treatment and metabolic surgery can be appropriate alternatives or complements. Compare them through an individualized long-term plan.
GLP-1 Brands & Reviews
- #1
CoreAge Rx
Editorial score: 9.8/10
CoreAge Rx offers clinician-reviewed compounded weight care. Compare the annual offer from $79/month for semaglutide or $129/month for tirzepatide with the full payment, dispensing details and refund conditions.
Semaglutide from $79/mo · Tirzepatide from $129/mo
Published
- Online prescribing and pharmacy fulfillment
- Dated first-party sources in the review
Questions to resolve
- Confirm full medication and care cost
- Verify local eligibility and ongoing support
- #2
SuperHealthy Rx
Editorial score: 9.6/10
SuperHealthy Rx advertises compounded semaglutide at $85/month and tirzepatide at $135/month, with a provider visit and shipping included. Confirm the current offer, billing term and state eligibility.
Semaglutide: $85/month advertised · Tirzepatide: $135/month advertised
Published
- Online prescribing and pharmacy fulfillment
- Dated first-party sources in the review
Questions to resolve
- Confirm full medication and care cost
- Verify local eligibility and ongoing support
- #3
Likeness Rx
Editorial score: 9.4/10
Likeness Rx offers online access to compounded semaglutide and tirzepatide. Its public page lists semaglutide from $79/month; tirzepatide from $129/month.
Semaglutide from $79/month · Tirzepatide from $129/month
Published
- Online prescribing and pharmacy fulfillment
- Dated first-party sources in the review
Questions to resolve
- Confirm full medication and care cost
- Verify local eligibility and ongoing support
- #4
Henry Meds
Editorial score: 9.3/10
Henry describes cash-pay plans bundling visits, medicine, supplies and ongoing care. Its multi-month cancellation terms can differ from its monthly plans.
Complete current quote needed
Published
- Telehealth and weight care
- Dated first-party sources in the review
Questions to resolve
- Confirm full medication and care cost
- Verify local eligibility and ongoing support
- #5
Hims
Editorial score: 9.1/10
Hims currently publishes a weight-loss membership with approved product options and medication billed separately. Older compounded-only descriptions do not capture its current offer.
Membership, medicine extra
Published
- Telehealth and weight care
- Dated first-party sources in the review
Questions to resolve
- Confirm full medication and care cost
- Verify local eligibility and ongoing support
Publisher preference scores. Comparison method and commercial relationships.
At a glance
- A contraindication to one medicine does not answer which alternative is right.
- Surgery has its own eligibility, risks and follow-up requirements.
- Supplements do not replace established obesity treatment.
Define why a change is needed
The reason could be an adverse effect, a contraindication, cost, access, insufficient response or preference. These are different problems and can lead to different solutions.
NIDDK describes several prescription weight-management options. A clinician should review indications, other medicines and health history before selecting one.
Sources: NIDDK: prescription medications for weight managementNIH: weight-loss dietary supplements
Compare complete treatment pathways
Metabolic or bariatric surgery can be considered within specialist assessment. It requires preparation, discussion of procedure-specific risks and ongoing nutritional and clinical follow-up.
A trial comparing drugs is not a head-to-head comparison with surgery. Long-term treatment choices depend on suitability, access, durability and the care required after the initial intervention.
Sources: NIDDK: prescription medications for weight managementNIH: weight-loss dietary supplements
Keep the transition supported
If medication is paused or discontinued, ask how appetite changes and recurrence of symptoms will be monitored. A sustainable plan includes a clinician contact, food and activity support and a path back into care.
Sources: NIDDK: prescription medications for weight managementNIH: weight-loss dietary supplements
Sources and review boundaries
Source check dates are listed below. First-party pages support descriptions of a service’s public offer; medical references support the educational context. They do not establish an independent clinical audit of a provider. This is general education, not personal medical advice; no named licensed clinical reviewer has reviewed this article.
- NIDDK: prescription medications for weight managementMedical or regulatory source · Source reviewed ·
- NIH: weight-loss dietary supplementsMedical or regulatory source · Source reviewed ·
Related Articles
GLP-1 medicines before surgery: what to tell the anesthesia team
Tell the anesthesia and procedural team about GLP-1 use early. Current multisociety guidance calls for an individualized plan rather than a blanket stop rule.
What to do when a GLP-1 shipment arrives warm
If an injectable medicine arrives warm, damaged or without clear instructions, contact the pharmacy before using it. The product and actual shipping conditions matter.
Alcohol on semaglutide: risks and questions for your prescriber
There is no alcoholic drink proven safest on a GLP-1. Alcohol can complicate nausea, hydration, blood sugar and the health conditions being treated.
Alcohol on tirzepatide: risks and questions for your prescriber
There is no alcoholic drink proven safest on a GLP-1. Alcohol can complicate nausea, hydration, blood sugar and the health conditions being treated.
Semaglutide compounding pharmacies: sourcing, rules and open questions
Compounded semaglutide and tirzepatide are not FDA-approved. Resolved shortages changed the basis for routine copies, and a pharmacy registration is not approval of its product.
Tirzepatide compounding pharmacies: sourcing, rules and open questions
Compounded semaglutide and tirzepatide are not FDA-approved. Resolved shortages changed the basis for routine copies, and a pharmacy registration is not approval of its product.
By Chief Medical Correspondent. Original publication date was not recorded. Updates are recorded when content changes.